Serum Institute of India to resume clinical trials of AstraZeneca-Oxford's COVID-19 vaccine after DGCI nod

The Pune-based Serum Institute of India (SII) is all set to resume the clinical trials of AstraZeneca-Oxford's COVID-19 vaccine candidate AZD1222 after receiving permission from the Drugs Controller General of India (DCGI), the company confirmed on Saturday.